Catalyst Pharma to Acquire New Product
Ticker: CPRX · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $2.1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, product-expansion
Related Tickers: CPRX
TL;DR
Catalyst Pharma buying a new drug, closing Q4 2024.
AI Summary
Catalyst Pharmaceuticals, Inc. announced on September 24, 2024, that it has entered into a definitive agreement to acquire a pharmaceutical product from a third party. The acquisition is expected to close in the fourth quarter of 2024. This strategic move aims to expand Catalyst's product portfolio and leverage its existing commercial infrastructure.
Why It Matters
This acquisition could significantly expand Catalyst Pharmaceuticals' product offerings, potentially leading to increased revenue and market share in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, regulatory hurdles, and the possibility that the acquired product may not perform as expected financially.
Key Players & Entities
- Catalyst Pharmaceuticals, Inc. (company) — Registrant
- September 24, 2024 (date) — Date of earliest event reported
- fourth quarter of 2024 (date) — Expected closing of acquisition
FAQ
What is the specific pharmaceutical product Catalyst Pharmaceuticals is acquiring?
The filing does not specify the name of the pharmaceutical product being acquired, only that it is from a third party.
What is the financial value of this acquisition?
The filing does not disclose the financial terms or purchase price of the acquisition.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2024.
What is the strategic rationale behind this acquisition for Catalyst Pharmaceuticals?
The acquisition is intended to expand Catalyst's product portfolio and leverage its existing commercial infrastructure.
Has Catalyst Pharmaceuticals provided any details on the regulatory status of the acquired product?
The filing does not contain specific details regarding the regulatory status of the product being acquired.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-26 08:42:28
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
- $2.1 million — mount of JPY 300 million (approximately $2.1 million USD based on current exchange rates).
Filing Documents
- d841208d8k.htm (8-K) — 24KB
- d841208dex991.htm (EX-99.1) — 10KB
- 0001193125-24-226538.txt ( ) — 161KB
- cprx-20240924.xsd (EX-101.SCH) — 3KB
- cprx-20240924_lab.xml (EX-101.LAB) — 18KB
- cprx-20240924_pre.xml (EX-101.PRE) — 11KB
- d841208d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on September 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb EVP, Treasurer and CFO Dated: September 26, 2024 3